LEO Pharma Inc. Donates $25,000 to New Jersey Pandemic Relief Fund

Madison, N.J., April 28, 2020 – LEO Pharma Inc. today announced a donation of $25,000 to  the New Jersey Pandemic Relief Fund (NJPRF) supporting resources to fight the medical, social, and economic impact of COVID-19 in communities across the state. LEO Pharma Inc. is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in medical dermatology, based in Madison, N.J.

NJPRF provides grants to existing organizations “with a demonstrated track record of caring for vulnerable communities” with 100% of donations providing essential services to those in need and helping those on the front lines of the COVID-19 pandemic response, including the healthcare community. NJPRF is hosted by the Community Foundation of New Jersey.

“COVID-19 continues to take a significant toll on New Jersey families and neighborhoods, and we hope our donation can provide some relief to those who are most in need,“ said Christopher Posner, President and CEO, LEO Pharma Inc. “As the pandemic evolves affecting New Jersey and beyond, LEO Pharma Inc. remains committed to supporting our U.S. employees, serving healthcare providers and delivering medicines for people affected by skin conditions.”

Learn more about the NJPRF at https://njprf.org/. Find additional information about LEO Pharma Inc.’s pandemic response as well as LEO Pharma A/S updates on COVID-19.

About LEO Pharma Inc. and LEO Pharma A/S
LEO Pharma Inc. is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology. LEO Pharma products have been available in the U.S. since 1994, and the company opened the U.S. affiliate in January 2010. LEO Pharma A/S is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.

Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: leo-pharma.com.

Rhonda Sciarra
Associate Director, Global External Communications

MAT-34226. April 2020.